在hERG-T618功能获取突变中对电流的amiodarone作用的表征
Min Lin1, Cuiyun Li1, Chao Lin1
1Department of Cardiology, People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, 350004, China.
Open life sciences
|November 13, 2023
概括
在HEK293细胞中,阿米奥达龙 (Ami) 对hERG-T618I通道的抑制作用较弱,而与野生类型 (WT) 通道相比. 这项研究调查了阿米奥达龙.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 心血管生理学心血管生理学
背景情况:
- 这种hERG通道对于心脏再极化至关重要.
- 在hERG中的突变,如T618I,可以导致心律失常.
- 阿米奥达龙是一种抗心律失常药物,已知对离子通道有影响.
研究的目的:
- 为了研究阿米奥达龙对hERG-T618I突变通道的影响.
- 为了比较阿米奥达龙对hERG-T618I和野生型 (WT) hERG通道的抑制作用.
主要方法:
- 用hERG-T618I和WT通道等质体感染了HEK293细胞.
- 采用了细胞外局部输液和全细胞补丁技术.
- 用阿米奥达龙 (10μM) 来评估其对离子电流的影响.
主要成果:
- 阿米奥达龙对WT hERG通道表现出比对hERG-T618I通道 (P <0.05) 更大的减速作用.
- 与WT相比,amiodarone的半抑制度在T618I突变体中大约是WT的1.82倍 (P <0.05).
- 阿米奥达龙减少了突变通道的STEP电流,并恢复了部分不激活,同时减少了稳定状态激活.
结论:
- 阿米奥达龙抑制HEK293细胞中的hERG-T618I电流,但与WT通道相比,其效果较弱.
- 这些发现表明hERG-T618I突变对阿米奥达龙抑制作用的敏感性差异.
- 这项研究提供了有关hERG通道病变的药物通道相互作用的见解.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
G-Protein Gated Ion Channels
4.6K
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
Sensory...
4.6K
Heart Failure Drugs: Inotropic Agents
598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
847
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
847
Cardiac Action Potential
1.5K
Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
1.5K


